Cargando…

BCL2 Inhibition: A New Paradigm for the Treatment of AML and Beyond

Altering the natural history of acute myeloid leukemia (AML) in unfit and older patients has proved a highly challenging hurdle, despite several decades of concerted clinical trial effort. The arrival of venetoclax (VEN) to the clinical stage represents the most important therapeutic advance to date...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Andrew H., Roberts, Andrew W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256369/
https://www.ncbi.nlm.nih.gov/pubmed/37304937
http://dx.doi.org/10.1097/HS9.0000000000000912
_version_ 1785057089169653760
author Wei, Andrew H.
Roberts, Andrew W.
author_facet Wei, Andrew H.
Roberts, Andrew W.
author_sort Wei, Andrew H.
collection PubMed
description Altering the natural history of acute myeloid leukemia (AML) in unfit and older patients has proved a highly challenging hurdle, despite several decades of concerted clinical trial effort. The arrival of venetoclax (VEN) to the clinical stage represents the most important therapeutic advance to date for older patients with AML. In this review, we will explain how and why VEN works, summarize its remarkable pathway to regulatory approval, and highlight the key milestones that have been important for its successful development in AML. We also provide perspectives on some of the challenges associated with using VEN in the clinic, emerging knowledge regarding mechanisms of treatment failure, and current clinical research directions likely to shape how this drug and others in this new class of anticancer agents are used in the future.
format Online
Article
Text
id pubmed-10256369
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-102563692023-06-10 BCL2 Inhibition: A New Paradigm for the Treatment of AML and Beyond Wei, Andrew H. Roberts, Andrew W. Hemasphere Review Article Altering the natural history of acute myeloid leukemia (AML) in unfit and older patients has proved a highly challenging hurdle, despite several decades of concerted clinical trial effort. The arrival of venetoclax (VEN) to the clinical stage represents the most important therapeutic advance to date for older patients with AML. In this review, we will explain how and why VEN works, summarize its remarkable pathway to regulatory approval, and highlight the key milestones that have been important for its successful development in AML. We also provide perspectives on some of the challenges associated with using VEN in the clinic, emerging knowledge regarding mechanisms of treatment failure, and current clinical research directions likely to shape how this drug and others in this new class of anticancer agents are used in the future. Lippincott Williams & Wilkins 2023-06-08 /pmc/articles/PMC10256369/ /pubmed/37304937 http://dx.doi.org/10.1097/HS9.0000000000000912 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-sa/4.0/This is an open access article distributed under the Creative Commons Attribution-ShareAlike License 4.0 (https://creativecommons.org/licenses/by-sa/4.0/) , which allows others to remix, tweak, and build upon the work, even for commercial purposes, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Review Article
Wei, Andrew H.
Roberts, Andrew W.
BCL2 Inhibition: A New Paradigm for the Treatment of AML and Beyond
title BCL2 Inhibition: A New Paradigm for the Treatment of AML and Beyond
title_full BCL2 Inhibition: A New Paradigm for the Treatment of AML and Beyond
title_fullStr BCL2 Inhibition: A New Paradigm for the Treatment of AML and Beyond
title_full_unstemmed BCL2 Inhibition: A New Paradigm for the Treatment of AML and Beyond
title_short BCL2 Inhibition: A New Paradigm for the Treatment of AML and Beyond
title_sort bcl2 inhibition: a new paradigm for the treatment of aml and beyond
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256369/
https://www.ncbi.nlm.nih.gov/pubmed/37304937
http://dx.doi.org/10.1097/HS9.0000000000000912
work_keys_str_mv AT weiandrewh bcl2inhibitionanewparadigmforthetreatmentofamlandbeyond
AT robertsandreww bcl2inhibitionanewparadigmforthetreatmentofamlandbeyond